Diabetes, Metabolic Syndrome and Obesity (Dec 2019)
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Abstract
Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla 90110, Thailand*These authors contributed equally to this workCorrespondence: Ramzi A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UKTel +44 113 343 7475Email [email protected]: In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.Keywords: oral semaglutide, type 2 diabetes, treatment, glucagon-like peptide 1
